object
hepat
c
viru
hcv
infect
caus
chronic
liver
diseas
major
public
health
problem
worldwid
aim
studi
evalu
potenti
monascu
pigment
deriv
deriv
microbi
secondari
metabolit
synthes
polyketid
monascu
spp
hcv
antivir
agent
method
perform
vitro
rnadepend
rna
polymeras
rdrp
assay
screen
hcv
rdrp
inhibitor
antihcv
activ
rdrp
inhibitor
hcvreplic
cell
evalu
quantif
rna
viral
genom
molecular
dock
analysi
perform
predict
bind
site
select
rdrp
inhibitor
identifi
monascu
pigment
deriv
inhibitor
hcv
rdrp
group
monascu
orang
pigment
mop
amino
acid
deriv
reactiv
oxygen
moieti
chang
amino
acid
significantli
inhibit
hcv
replic
combin
mop
deriv
phe
val
leu
conjug
interferon
ifn
inhibit
hcv
replic
ifna
treatment
alon
lastli
molecular
dock
studi
indic
inhibitor
may
bind
thumb
subdomain
alloster
site
antivir
activ
mop
deriv
relat
modul
mevalon
pathway
sinc
mevalonateinduc
increas
hcv
replic
suppress
mop
compound
conclus
result
identifi
amino
acid
deriv
mop
potenti
antihcv
agent
suggest
combin
ifna
might
offer
altern
strategi
control
hcv
replic
hepat
c
viru
hcv
infect
million
peopl
worldwid
often
associ
chronic
hepat
lead
liver
cirrhosi
hepatocellular
carcinoma
current
pegyl
interferon
ifn
nucleosid
analogu
ribavirin
use
standard
therapi
treat
chronic
hcv
infect
howev
ifna
alon
combin
ribavirin
often
lead
rang
side
effect
sustain
virolog
respons
rate
combin
therapi
pegyl
ifna
ribavirin
particularli
infect
hcv
genotyp
therefor
urgent
need
develop
altern
antihcv
agent
especi
patient
respond
ifna
therapi
hcv
envelop
rna
viru
positivesens
singlestrand
rna
genom
kb
viral
genom
consist
one
long
open
read
frame
orf
flank
untransl
region
utr
end
genom
orf
encod
singl
polyprotein
amino
acid
proteolyt
process
cellular
viral
proteas
polypeptid
correspond
viral
structur
nonstructur
ns
protein
kda
hcv
protein
rnadepend
rna
polymeras
rdrp
activ
key
player
hcv
rna
replic
rdrp
activ
present
mammalian
cell
offer
opportun
identifi
select
inhibitor
hcv
rdrp
crystal
structur
hcv
resembl
right
hand
shape
finger
thumb
palm
domain
similar
polymeras
last
decad
research
begun
develop
nucleosid
nonnucleosid
analogu
inhibitor
target
activ
site
palm
subdomain
alloster
site
thumb
subdomain
microbi
secondari
metabolit
varieti
biolog
properti
make
use
antibiot
anticanc
drug
antivir
drug
applic
monascusfer
product
first
mention
monograph
chines
medicin
produc
monascu
speci
histor
use
treat
indigest
muscl
bruis
dysenteri
monacolin
k
also
known
lovastatin
major
secondari
metabolit
produc
monascu
spp
potent
inhibitor
hmgcoa
reductas
monascu
pigment
also
secondari
metabolit
synthes
polyketid
monascu
spp
six
major
monascu
pigment
includ
yellow
pigment
monascin
ankaflavin
orang
pigment
monascorubin
c
h
rubropunctatin
c
h
red
pigment
monascropunctamin
rubropunctamin
monascu
pigment
use
food
addit
tradit
medicin
east
asian
countri
includ
china
korea
japan
taiwan
pigment
mani
use
biolog
activ
antimicrobi
tumour
suppress
immunosuppress
activ
well
hypolipidaem
activ
howev
mechan
action
well
defin
report
monascu
pigment
deriv
antihcv
activ
compound
identifi
screen
microbi
secondari
metabolit
hcv
rdrp
inhibitor
demonstr
group
monascu
orang
pigment
mop
deriv
effect
inhibit
rdrp
activ
interf
mevalon
synthesi
pathway
therebi
suppress
hcv
replic
cell
harbour
hcv
genotyp
subgenom
replicon
cell
infect
genotyp
hcv
human
hepatoma
cell
line
grown
dulbecco
modifi
eagl
medium
dmem
biowhittak
walkersvil
usa
supplement
describ
previous
cell
line
support
stabl
autonom
replic
genotyp
hcv
subgenom
replicon
maintain
dmem
mgml
describ
previous
monascu
pigment
reagent
mop
amino
acid
deriv
aad
produc
use
monascu
sp
kccm
purifi
thin
layer
chromatographi
describ
previous
puriti
mop
aad
evalu
hplc
describ
previous
purifi
mop
aad
compound
store
mm
stock
solut
dmso
dilut
serumfre
medium
use
final
dmso
concentr
exceed
ifna
purchas
sigmaaldrich
st
loui
mo
usa
infecti
hcv
rna
genotyp
hcv
prepar
vitro
transcript
use
megascript
kit
ambion
austin
tx
usa
electropor
cell
describ
previous
cell
infect
viru
multipl
infect
describ
previous
evalu
antivir
activ
indic
dose
ifna
andor
mop
aad
ad
dmem
contain
fetal
bovin
serum
day
cell
harvest
rel
hcv
genom
rna
level
assess
quantit
revers
transcript
realtim
pcr
qrtpcr
halfmaxim
inhibitori
concentr
ic
valu
determin
fit
data
threeparametr
sigmoid
function
use
sigmaplot
softwar
version
systat
softwar
inc
richmond
ca
usa
cytotox
mop
deriv
measur
use
bromid
mtt
reagent
describ
previous
briefli
cell
grown
plate
confluenc
incub
h
mop
deriv
variou
concentr
complet
dmem
formazan
format
measur
read
optic
absorb
nm
micropl
reader
fluostar
optima
bmg
labtech
gmbh
offenburg
germani
recombin
hcv
protein
ntermin
hexahistidin
tag
express
escherichia
coli
purifi
describ
previous
vitro
rna
polymeras
activ
assay
perform
streptavidinco
flashplat
perkinelm
life
analyt
scienc
waltham
usa
describ
previous
brief
reaction
perform
ml
total
volum
mixtur
contain
mm
trishcl
ph
mm
nacl
mm
mgcl
mm
dtt
u
rnase
inhibitor
promega
madison
wi
usa
mm
utp
mg
poli
rna
pmol
biotinly
oligo
u
mci
p
utp
cimmol
amersham
pharmacia
biotech
piscataway
nj
usa
pmol
purifi
reaction
mixtur
incub
h
stop
reaction
ml
mm
edta
ad
min
incub
room
temperatur
reaction
mixtur
remov
plate
wash
phosphatebuff
salin
captur
label
rna
product
measur
perkinelm
topcount
scintil
counter
assay
perform
use
hmgcoa
reductas
assay
kit
sigmaaldrich
accord
manufactur
protocol
enzym
activ
base
nadph
oxid
determin
measur
absorb
nm
min
use
spectrophotomet
fluostar
optima
bmg
labtech
gmbh
reaction
perform
presenc
deriv
mop
mm
pravastatin
mm
sigmaaldrich
total
cholesterol
extract
cell
describ
previous
cholesterol
content
determin
amplexr
cholesterol
assay
kit
invitrogen
carlsbad
ca
usa
mevalon
prepar
hydrolysi
mevalonolacton
sigmaaldrich
koh
previous
describ
viral
rna
genom
quantif
total
rna
extract
cell
hcvinfect
cell
use
trizol
ls
reagent
invitrogen
hcv
rna
level
sampl
quantifi
qrtpcr
use
primer
pair
taqman
probe
target
region
within
hcv
utr
describ
previous
sun
et
al
western
blot
analysi
cell
hcvinfect
cell
resuspend
lysi
buffer
contain
mm
trishcl
ph
mm
nacl
triton
edtafre
proteas
inhibitor
cocktail
roch
diagnost
gmbh
mannheim
germani
cell
lysat
contain
equal
amount
protein
resolv
sdspage
transfer
nitrocellulos
membran
immunoblot
virogen
watertown
usa
antibodi
describ
previous
demonstr
equal
load
cell
lysat
atubulin
measur
western
blot
analysi
use
antiatubulin
antibodi
oncogen
research
product
cambridg
usa
blot
develop
use
enhanc
chemiluminesc
western
blot
system
ge
healthcar
life
scienc
piscataway
nj
usa
describ
previous
quantit
analys
western
blot
perform
use
scion
imag
softwar
scion
co
frederick
md
usa
crystal
structur
hcv
protein
protein
data
bank
code
use
molecular
dock
simul
analys
structur
kept
rigid
wherea
torsion
bond
mop
aad
set
free
flexibl
dock
affin
grid
bind
pocket
construct
use
grid
space
grid
map
consist
grid
point
use
find
bind
posit
mop
aad
hcv
molecular
dock
simul
molecular
dock
perform
global
genet
algorithm
combin
local
minim
lamarckian
genet
algorithm
explor
compound
conform
space
dock
job
trial
final
dock
conform
cluster
use
toler
rootmeansquar
deviat
paramet
set
default
valu
dock
conform
properli
orient
toward
hcv
inhibitor
bind
pocket
select
free
energi
bind
estim
molecular
graphic
inhibitor
bind
pocket
refin
dock
model
select
mop
aad
gener
use
pymol
softwar
packag
hcv
rdrp
essenti
enzym
hcv
replic
therefor
promis
antivir
drug
target
block
viral
genom
replic
screen
inhous
microbi
secondari
metabolit
librari
identifi
mop
secondari
metabolit
figur
inhibitor
hcv
rdrp
activ
screen
librari
perform
vitro
rdrp
assay
use
recombin
vitro
rdrp
assay
carri
flashplat
coat
streptavidin
use
poli
rnabiotinyl
oligo
u
substrat
presenc
mm
librari
compound
shown
figur
b
natur
mop
inhibit
activ
mm
concentr
attempt
improv
inhibitori
potenc
produc
variou
aad
mop
aromat
ring
oxygen
mop
chang
differ
amino
acid
figur
deriv
test
rdrp
inhibitori
activ
among
result
mop
aad
found
deriv
contain
asn
ly
phe
gli
ala
val
leu
ile
side
chain
greater
inhibitori
potenc
parent
mop
howev
activ
still
lower
benzothiadiazinylquinon
inhibit
nm
potent
hcv
inhibitor
design
target
palm
site
polymeras
antihcv
activ
monascu
pigment
deriv
jac
consid
novel
potenti
microbi
secondari
metabolit
antihcv
agent
proceed
character
structurefunct
relationship
test
hcv
inhibitori
effect
abovedescrib
mop
aad
cell
harbour
hcv
genotyp
subgenom
replicon
replicon
consist
hcv
intern
ribosom
entri
site
ire
direct
express
select
neo
r
marker
encephalomyocard
viru
ire
direct
express
hcv
ns
protein
requir
hcv
replic
figur
top
panel
cell
treat
mm
mop
aad
h
remain
steadyst
level
protein
determin
western
blot
analysi
shown
figur
among
select
group
mop
aad
inhibit
rdrp
activ
vitro
ly
phe
val
leu
ile
deriv
also
inhibit
hcv
replic
cell
harbour
hcv
subgenom
replicon
rna
treatment
cell
posit
control
ifna
iuml
mop
aad
reduc
protein
level
differ
degre
ifna
reduc
reduct
aad
ly
phe
val
leu
ile
condit
assay
none
mop
compound
significantli
affect
cell
prolifer
mm
concentr
assess
colorimetr
mtt
assay
data
shown
notabl
contrast
vitro
rdrp
assay
result
parent
mop
compound
significantli
reduc
hcv
protein
express
level
huh
cell
might
due
lower
affin
rdrp
inabl
pass
plasma
membran
next
confirm
antihcv
activ
five
select
mop
deriv
ly
phe
val
leu
ile
deriv
measur
hcv
subgenom
rna
level
realtim
qrt
pcr
hcv
rna
level
decreas
treatment
mm
mop
deriv
figur
final
select
mop
phe
val
leu
deriv
character
mechan
hcv
inhibit
hcvinfect
cell
use
hcv
infect
system
establish
genotyp
hcv
clone
yield
infecti
hcv
viru
cell
line
combin
therapi
pegyl
ifna
ribavirin
current
standard
therapi
treatment
hcv
infect
also
sought
evalu
potenti
mop
aad
act
combin
ifna
hcvinfect
cell
treat
mm
mop
aad
alon
combin
ifna
iuml
h
hcv
genom
level
analys
realtim
qrt
pcr
shown
figur
rna
combin
ifna
inhibit
hcv
replic
dosedepend
manner
ic
valu
mm
figur
also
monitor
viral
protein
express
western
blot
analysi
shown
figur
b
inset
mopleu
deriv
reduc
express
dosedepend
manner
lastli
compound
display
signific
cytotox
concentr
mm
decreas
cell
viabil
mm
assess
mtt
cell
viabil
assay
figur
togeth
result
demonstr
mop
aad
antivir
activ
genotyp
hcv
infect
model
genotyp
hcv
subgenom
replicon
system
figur
suggest
potenti
novel
hcv
antivir
drug
use
combin
ifna
understand
molecular
mechan
rdrp
inhibit
select
mop
aad
perform
molecular
dock
inhibitor
crystal
structur
hcv
inhibitor
complex
mop
aad
phe
ile
leu
deriv
figur
success
dock
thumb
subdomain
away
polymeras
activ
site
palm
domain
figur
shown
figur
hydrogen
bond
interact
site
defin
amino
acid
propenyl
moieti
mop
aad
bound
surfac
one
hydrophob
pocket
defin
predict
bind
mode
moieti
similar
ethylfuran
moieti
refer
compound
hexanoyl
group
mop
aad
like
ring
refer
compound
buri
narrow
deep
hydrophob
pocket
defin
lastli
two
hydrogen
bond
oxygen
atom
carboxyl
group
inhibitor
side
chain
also
observ
carboxyl
acid
moieti
refer
compound
locat
inhibitorbind
site
suggest
bind
inhibitor
could
interfer
conform
chang
essenti
hcv
polymeras
activ
interfer
mevalon
pathway
mop
aad
lipid
metabol
cholesterol
synthesi
play
critic
role
hcv
replic
hmgcoa
reductas
catalys
convers
hmgcoa
mevalon
ratelimit
step
cholesterol
biosynthesi
variou
inhibitor
enzym
previous
test
antihcv
activ
particular
lovastatin
one
monascusproduc
secondari
metabolit
shown
effect
suppress
hcv
replic
inhibit
interact
hcv
host
protein
also
observ
lovastatin
treatment
mm
h
reduc
viral
genom
abund
hcvreplic
cell
data
shown
confirm
previou
report
current
known
whether
mop
like
lovastatin
also
interfer
cholesterol
biosynthesi
assess
possibl
mop
aad
may
inhibit
hcv
replic
inhibit
cholesterol
biosynthesi
first
perform
vitro
hmgcoa
reductas
assay
hcv
replicationsupport
cell
shown
figur
b
mop
deriv
phe
val
leu
deriv
observ
hmgcoa
reductas
inhibitori
activ
even
high
concentr
mm
pravastatin
hmgcoa
reductas
inhibitor
significantli
decreas
enzym
activ
concentr
mm
mevalon
pathway
acetylcoa
convert
hmgcoa
mevalon
farnesyl
diphosph
squalen
cholesterol
figur
product
geranylgeranyl
lipid
cholesterol
mevalon
pathway
import
hcv
rna
replic
consist
found
mevalon
supplement
hcvreplic
cell
increas
hcv
subgenom
rna
level
figur
result
prompt
us
investig
whether
mop
aad
block
hcv
replic
inhibit
cholesterol
biosynthet
pathway
downstream
mevalon
test
possibl
examin
whether
increas
hcv
replic
addit
mevalon
suppress
mop
aad
cell
harbour
hcv
subgenom
replicon
incub
mm
mevalon
absenc
presenc
mm
phe
val
leu
mop
aad
day
cell
harvest
hcv
subgenom
rna
level
analys
realtim
qrtpcr
shown
figur
c
hcv
rna
level
increas
addit
mevalon
howev
mevalonateinduc
increas
complet
block
mop
aad
treatment
moreov
increas
intracellular
cholesterol
caus
mevalon
supplement
also
inhibit
mop
aad
treatment
cholesterol
level
reduc
level
mocktreat
cell
figur
togeth
result
suggest
addit
direct
inhibit
rdrp
activ
mop
aad
compound
also
inhibit
hcv
replic
interf
cholesterol
biosynthet
pathway
downstream
hmgcoa
reductas
step
microbi
secondari
metabolit
shown
effect
anticanc
antimicrobi
agent
treatment
metabol
diseas
hypercholesterolaemia
natur
product
attract
develop
antivir
drug
treat
control
viral
infecti
diseas
previous
overlook
antivir
research
studi
screen
inhous
librari
microbi
secondari
metabolit
found
seri
mop
aad
antihcv
activ
identifi
two
novel
activ
mop
aad
inhibit
hcv
rdrp
activ
interfer
mevalon
pathway
inhibitori
activ
found
contribut
suppress
hcv
replic
current
four
differ
alloster
bind
site
hcv
nonnucleosid
inhibitor
nni
identifi
two
site
thumb
domain
two
site
palm
domain
mop
leu
ile
phe
aad
predict
bind
primarili
thumb
subdomain
site
ii
name
nni
site
ii
away
activ
site
protein
mop
aad
fail
dock
three
nni
site
show
common
bind
pattern
share
previous
report
inhibitor
known
bind
nnibind
site
iii
iv
data
shown
pharmacophor
hcv
nni
bind
thumb
subdomain
site
ii
compos
hydrogenbond
interact
site
hydrophob
caviti
appear
occupi
carboxyl
acid
residu
prophenyl
residu
mop
aad
respect
among
two
predict
interact
part
mop
aad
carboxyl
acid
residu
seem
critic
inhibit
sinc
mop
lack
carboxyl
acid
residu
show
compar
lower
inhibitori
activ
detect
antihcv
activ
hcvreplic
cell
molecular
dock
simul
show
parent
mop
compound
make
hydrogen
bond
nni
bind
site
like
inhibitor
bind
nnibind
site
upper
section
hcv
thumb
domain
like
prevent
polymeras
adopt
close
conform
requir
product
polymer
elong
genotypedepend
antivir
activ
due
polymorph
major
obstacl
develop
nni
hcv
rdrp
inde
except
inhibitor
bind
nni
site
iv
palm
domain
activ
nni
nongenotyp
hcv
limit
mop
aad
select
present
studi
demonstr
similar
antivir
potenc
hcv
genotyp
subgenom
replicon
cell
genotyp
hcvinfect
cell
suggest
bind
mode
inhibitor
limit
genotyp
polymeras
howev
studi
need
determin
whether
mop
deriv
provid
novel
scaffold
bind
thumb
subdomain
alloster
site
genotyp
well
addit
genotyp
divers
emerg
resist
mutant
anoth
obstacl
develop
nni
instanc
treatment
patient
nni
site
ii
inhibitor
filibuvir
clinic
trial
result
select
resist
mutant
mutat
molecular
dock
simul
predict
also
involv
bind
select
mop
aad
site
ii
hydrophob
pocket
thu
interest
investig
whether
mop
aad
show
crossresist
nni
site
ii
inhibitor
mop
aad
would
addit
combin
choic
nni
cocktail
therapi
sever
line
evid
suggest
cellular
lipid
cholesterol
metabol
play
either
direct
indirect
role
hcv
life
cycl
particular
cholesterol
biosynthesi
propos
integr
part
hcv
rna
replic
occur
lipid
raft
addit
hcv
entri
lowdens
lipoprotein
receptor
viral
assembl
occur
surfac
lipid
droplet
also
link
cholesterol
biosynthesi
accordingli
variou
inhibitor
hmgcoa
reductas
shown
suppress
hcv
replic
result
suggest
antihcv
activ
mop
aad
phe
val
leu
deriv
might
also
partial
due
abil
interfer
mevalon
biosynthet
pathway
key
enzym
mevalon
cholesterol
pathway
hmgcoa
reductas
inhibit
mop
deriv
howev
increas
hcv
rna
level
induc
mevalon
supplement
inhibit
mop
aad
previous
suggest
geranylgeranyl
host
factor
requir
target
hcv
intracellular
membran
structur
form
rna
replicas
complex
previou
studi
also
demonstr
addit
cholesterol
fail
rescu
hcv
rna
replic
presenc
lovastatin
thu
like
mop
aad
prevent
hcv
replic
part
block
gener
geranylgeranyl
precursor
sinc
hcv
interact
requir
hcv
replic
depend
geranylgeranyl
note
increas
intracellular
cholesterol
level
mevalonatetr
cell
decreas
upon
treatment
mop
aad
therefor
mop
aad
appear
capabl
inhibit
step
involv
convert
mevalon
cholesterol
enzym
convert
farnesyl
diphosph
geranylgeranyl
diphosph
summari
result
present
demonstr
mop
aad
effect
inhibit
hcv
replic
doublehit
strategi
includ
inhibit
hcv
rdrp
activ
interfer
mevalon
synthet
pathway
inhibit
hcv
amplif
may
provid
basi
success
antivir
therapi
use
mop
aad
deriv
microbi
secondari
metabolit
select
aad
mop
potenti
antivir
activ
ifna
suggest
combin
therapi
ifna
drug
may
offer
altern
strategi
control
hcv
replic
